Asymptomatic Inmune Thrombocytopenia associated with COVID-19
DOI:
https://doi.org/10.51481/amc.v63i4.1120Keywords:
COVID-19, SARS-CoV-2, Thrombocytopenia, Thrombocytopenic purpuraAbstract
The SARS-CoV-2 virus is a disease that produces multiple clinical manifestations. Abnormal hematologic findings, such as thrombocytopenia, have emerged as a complication of COVID-19.
Worldwide, series of cases of association between the SARS-CoV-2 virus and immune thrombocytopenia have been described; however, reported to date, it is the first case published in Costa Rica.
This clinical report describes the case of an elderly female admitted in the Centro Especializado para la Atención de pacientes COVID-19, one of the hospitals of the Caja Costarricense de Seguro Social. She was admitted with severe COVID-19, and during her hospital stay, she developed asymptomatic acute thrombocytopenia. The diagnosis of immune thrombocytopenia was made after excluding other diagnoses causing this sign. In addition of the protocolized management of COVID-19 with steroids and enoxaparin, she was treated with an additional cycle of dexamethasone and a dose of intravenous immunoglobulin. After this, she showed a complete recovery of the platelet count.
Downloads
References
Sadr S, SeyedAlinaghi S, Ghiasvand F, Nezhad M, Javadian N, Hossienzade R, et al. Isolated severe thrombocytopenia in a patient with COVID-19: A case report. ID Cases. 2020;21:e00820.
Cooper N, Ghanima W. Immune Thrombocytopenia. N Engl J Med. 2019;381:945-55.
Bhattacharjee S, Banerjee M. Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review. SN Compr Clin Med. 2020; 19:1-11.
Mahévas M, Moulis G, Andres E, Riviere E, Garzaro M, Crickx E, et al. Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol. 2020; vol 190 (4): e224-e229.
Ministerio de Salud. LS-VS-001 Lineamientos Nacionales para la Vigilancia de la enfermedad COVID-19. [Internet]. 2020 Dic 22. [cited 2021 Jul 3]. Available from: https://www.ministeriodesalud.go.cr/sobre_ministerio/prensa/docs/ls_vs_001_Version_17_Vigilancia_COVID19_22_12_2020.pdf
Humbert S, Razanamahery J, Payet-Revest C, Bouiller K, Chirouze C. COVID-19 as a cause of immune thrombocytopenia. Médecine et Maladies Infectieuses. 2020;50:459-60.
Carrillo R, Morales N, Ramírez F. Pseudotrombocitopenia: reporte de un caso y revisión de la bibliografía. Med Int Mex. 2009;25:163-8.
Stasi R. How to approach thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2012;1: 191-7.
Al-Nouri Z, Reese J, Terrell D, Vesely S, George J. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015;125:616-8.
Ortonobes S, López B, Solano M, Ferrández O. Toxicidad hematológica durante el tratamiento con albendazol. Enferm Infecc Microbiol Clin. 2016; 34:326-7.
Assinger, A. Platelets and infection - An emerging role of platelets in viral infection. Front Immunol 2014; 5:1-12.
Shragai T, Lebel E, Deshet D, Varon D, Avivi I, Kirgner I, Sarid N. Characteristics and outcomes of adults with cytomegalovirus-associated thrombocytopenia: a case series and literature review. Br J Haematol. 2020;191:863-7.
Nowalk A, Green M. Epstein-Barr Virus. Microbiol Spectr. 2016;4:1-8.
Neunert C, Terrell D, Arnold D, Buchanan G, Cines D, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019; 3:3829-66.
Almizraq R, Branch D. Efficacy and mechanism of intravenous immunoglobulin treatment for immune thrombocytopenia in adults. Ann Blood. 2021;6:1-20.
Published
Issue
Section
License
Copyright (c) 2022 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
